L Clifford Mcdonald

List of Publications by Year
in descending order

166 papers	25,449 citations	13865 67 h-index	6653 156 g-index
168 all docs	168 docs citations	168 times ranked	16097 citing authors

#	Article	IF	Citations
1	Repeated antigen testing among severe acute respiratory coronavirus virus 2 (SARS-CoV-2)â€“positive nursing home residents. Infection Control and Hospital Epidemiology, 2022, 43, 1918-1921.	1.8	4
2	Advancing Diagnostic Stewardship for Healthcare-Associated Infections, Antibiotic Resistance, and Sepsis. Clinical Infectious Diseases, 2022, 74, 723-728.	5.8	29
3	Development and Validation of an Enzyme Immunoassay for Detection and Quantification of SARS-CoV-2 Salivary IgA and IgG. Journal of Immunology, 2022, 208, 1500-1508.	0.8	19
4	Infectious Period of Severe Acute Respiratory Syndrome Coronavirus 2 in 17 Nursing Home Residentsâ€”Arkansas, Juneâ€“August 2020. Open Forum Infectious Diseases, 2021, 8, ofab048.	0.9	11
5	Framing Bacterial Genomics for Public Health (Care). Journal of Clinical Microbiology, 2021, 59, e0013521.	3.9	6
6	Diagnosed and Undiagnosed COVID-19 in US Emergency Department Health Care Personnel: AÂCross-sectional Analysis. Annals of Emergency Medicine, 2021, 78, 27-34.	0.6	7
7	Performance Evaluation of Serial SARS-CoV-2 Rapid Antigen Testing During a Nursing Home Outbreak. Annals of Internal Medicine, 2021, 174, 945-951.	3.9	59
8	Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER): Protocol for a Multisite Longitudinal Cohort Study. JMIR Research Protocols, 2021, 10, e31574.	1.0	17
9	Clinical Course of SARS-CoV-2 Infection in Adults with ESKD Receiving Outpatient Hemodialysis. Kidney360, 2021, 2, 1917-1927.	2.1	1
10	Association Between Antibiotic Use and Hospital-onset Clostridioides difficile Infection in US Acute Care Hospitals, 2006â€“2012: An Ecologic Analysis. Clinical Infectious Diseases, 2020, 70, 11-18.	5.8	59
11	Reinforcement of an infection control bundle targeting prevention practices for Clostridioides difficile in Veterans Health Administration nursing homes. American Journal of Infection Control, 2020, 48, 626-632.	2.3	3
12	Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. New England Journal of Medicine, 2020, 382, 1320-1330.	27.0	480
13	Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012â€“2017. New England Journal of Medicine, 2020, 382, 1309-1319.	27.0	344
14	Detection of Clostridioides difficile by Real-time PCR in Young Children Does Not Predict Disease. Hospital Pediatrics, 2020, 10, 555-562.	1.3	13
15	Digging Deep in the Microbiome to Diagnose Clostridioides difficile Infection. Clinical Chemistry, 2020, 66, 641-643.	3.2	2
16	The Challenges of TrackingClostridium difficileto Its Source in Hospitalized Patients. Clinical Infectious Diseases, 2019, 68, 210-212.	5.8	2
17	Hospital-level high-risk antibiotic use in relation to hospital-associated Clostridioides difficile infections: Retrospective analysis of 2016â€“2017 data from US hospitals. Infection Control and Hospital Epidemiology, 2019, 40, 1229-1235.	1.8	29
18	Toxin Enzyme Immunoassays Detect Clostridioides difficile Infection With Greater Severity and Higher Recurrence Rates. Clinical Infectious Diseases, 2019, 69, 1667-1674.	5.8	40

#	Article	IF	Citations
19	Assessing the social cost and benefits of a national requirement establishing antibiotic stewardship programs to prevent Clostridioides difficile infection in US hospitals. Antimicrobial Resistance and Infection Control, 2019, 8, 17.	4.1	5
20	A national survey of testing and management of asymptomatic carriage of C. difficile. Infection Control and Hospital Epidemiology, 2019, 40, 801-803.	1.8	6
21	Vital Signs:Epidemiology and Recent Trends in Methicillin-Resistant and in Methicillin-SusceptibleStaphylococcus aureusBloodstream Infections â€" United States. Morbidity and Mortality Weekly Report, 2019, 68, 214-219.	15.1	479
22	Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases, 2018, 66, e1-e48.	5.8	1,695
23	Risk of Subsequent Sepsis Within 90 Days After a Hospital Stay by Type of Antibiotic Exposure. Clinical Infectious Diseases, 2018, 66, 1004-1012.	5.8	122
24	Reply to Collins and Riley. Clinical Infectious Diseases, 2018, 67, 1640.	5.8	0
25	Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases, 2018, 66, 987-994.	5.8	900
26	Intestinal Carriage of Third-Generation Cephalosporin-Resistant and Extended-Spectrum Î²-Lactamase-Producing Enterobacteriaceae in Healthy US Children. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 234-240.	1.3	34
27	Vital Signs: Containment of Novel Multidrug-Resistant Organisms and Resistance Mechanisms â€" United States, 2006â€"2017. Morbidity and Mortality Weekly Report, 2018, 67, 396-401.	15.1	99
28	Point-Counterpoint: Active Surveillance for Carriers of Toxigenic Clostridium difficile Should Be Performed To Guide Prevention Efforts. Journal of Clinical Microbiology, 2018, 56, .	3.9	10
29	Transmission ofClostridium difficilefrom asymptomatically colonized or infected long-term care facility residents. Infection Control and Hospital Epidemiology, 2018, 39, 909-916.	1.8	38
30	Reply to Fabre et al. Clinical Infectious Diseases, 2018, 67, 1958-1959.	5.8	3
31	Diagnosing an Infection Control Risk. Clinical Infectious Diseases, 2017, 64, 1171-1173.	5.8	1
32	Risk Factors for Community-Associated Clostridium difficile Infection in Adults: A Case-Control Study. Open Forum Infectious Diseases, 2017, 4, ofx171.	0.9	67
33	Burden of Nursing Home-Onset Clostridium difficile Infection in the United States: Estimates of Incidence and Patient Outcomes. Open Forum Infectious Diseases, 2016, 3, ofv196.	0.9	43
34	Editorial Commentary: The Dawning of Microbiome Remediation for Addressing Antibiotic Resistance. Clinical Infectious Diseases, 2016, 62, 1487-1488.	5.8	17
35	Letter in Response to â€œQuestionable validity of the catheter-associated urinary tract infection metric used for value-based purchasingâ€• American Journal of Infection Control, 2016, 44, 369-370.	2.3	1
36	Active Surveillance and Isolation of Asymptomatic Carriers ofClostridium difficileat Hospital Admission. JAMA Internal Medicine, 2016, 176, 805.	5.1	4

#	Article	IF	Citations
37	Vital Signs: Preventing Antibioticâ€Resistant Infections in Hospitals â€" United States, 2014. American Journal of Transplantation, 2016, 16, 2224-2230.	4.7	22
38	Assessment of the Overall and Multidrug-Resistant Organism Bioburden on Environmental Surfaces in Healthcare Facilities. Infection Control and Hospital Epidemiology, 2016, 37, 1426-1432.	1.8	74
39	Diagnosis and Treatment of Clostridium difficile Infection. Infectious Diseases in Clinical Practice, 2016, 24, 3-10.	0.3	26
40	Intestinal microbiome disruption in patients in a long-term acute care hospital: A case for development of microbiome disruption indices to improve infection prevention. American Journal of Infection Control, 2016, 44, 830-836.	2.3	43
41	Prevalence of probiotic use among inpatients: A descriptive study of 145 U.S. hospitals. American Journal of Infection Control, 2016, 44, 548-553.	2.3	42
42	Vital Signs: Preventing Antibiotic-Resistant Infections in Hospitals â€" United States, 2014. Morbidity and Mortality Weekly Report, 2016, 65, 235-241.	15.1	58
43	Vital Signs: Preventing Antibiotic-Resistant Infections in Hospitals â€" United States, 2014. Morbidity and Mortality Weekly Report, 2016, 65, .	15.1	0
44	A Potential Cellular Explanation for the Increased Risk of Clostridium difficile Infection Due to Hypoalbuminemia: Reply Di Bella et al. Infection Control and Hospital Epidemiology, 2015, 36, 1480-1480.	1.8	1
45	The Costâ€"Benefit of Federal Investment in Preventing Clostridium difficile Infections through the Use of a Multifaceted Infection Control and Antimicrobial Stewardship Program. Infection Control and Hospital Epidemiology, 2015, 36, 681-687.	1.8	23
46	Causes, Burden, and Prevention of Clostridium difficile Infection. Infectious Diseases in Clinical Practice, 2015, 23, 281-288.	0.3	10
47	Burden ofClostridium difficileInfection in the United States. New England Journal of Medicine, 2015, 372, 825-834.	27.0	2,313
48	Uncovering the Role of Antibiotics in the Transmission of Multidrug-Resistant Organisms. JAMA Internal Medicine, 2015, 175, 633.	5.1	1
49	Burden of Clostridium difficile Infection in the United States. New England Journal of Medicine, 2015, 372, 2368-2370.	27.0	258
50	Predicting the Risk for Hospital-Onset Clostridium difficile Infection (HO-CDI) at the Time of Inpatient Admission: HO-CDI Risk Score. Infection Control and Hospital Epidemiology, 2015, 36, 695-701.	1.8	36
51	Association Between Outpatient Antibiotic Prescribing Practices and Community-Associated Clostridium difficile Infection. Open Forum Infectious Diseases, 2015, 2, ofv113.	0.9	61
52	Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials. Vaccine, 2015, 33, 6241-6249.	3.8	14
53	CDC Central-Line Bloodstream Infection Prevention Efforts Produced Net Benefits Of At Least $640ÂMillion During 1990â€"2008. Health Affairs, 2014, 33, 1040-1047.	5.2	11
54	Determinants of Clostridium difficile Infection Incidence Across Diverse United States Geographic Locations. Open Forum Infectious Diseases, 2014, 1, ofu048.	0.9	37

#	Article	IF	Citations
55	Strategies to PreventClostridium difficileInfections in Acute Care Hospitals: 2014 Update. Infection Control and Hospital Epidemiology, 2014, 35, 628-645.	1.8	175
56	Utility of a Commercial PCR Assay and a Clinical Prediction Rule for Detection of Toxigenic Clostridium difficile in Asymptomatic Carriers. Journal of Clinical Microbiology, 2014, 52, 315-318.	3.9	22
57	Clostridium difficile Infection Among Children Across Diverse US Geographic Locations. Pediatrics, 2014, 133, 651-658.	2.1	117
58	Strategies to PreventClostridium difficileInfections in Acute Care Hospitals: 2014 Update. Infection Control and Hospital Epidemiology, 2014, 35, S48-S65.	1.8	80
59	Strategies to Prevent Clostridium difficile Infections in Acute Care Hospitals: 2014 Update. Infection Control and Hospital Epidemiology, 2014, 35, 628-645.	1.8	106
60	Epidemiology of Community-AssociatedClostridium difficileInfection, 2009 Through 2011. JAMA Internal Medicine, 2013, 173, 1359.	5.1	378
61	Attributable Burden of Hospital-OnsetClostridium difficileInfection: A Propensity Score Matching Study. Infection Control and Hospital Epidemiology, 2013, 34, 588-596.	1.8	71
62	Assessment of Public Health Perspectives on Responding to an Emerging Pathogen. Journal of Public Health Management and Practice, 2013, 19, E27-E32.	1.4	7
63	Effect of Nucleic Acid Amplification Testing on Population-Based Incidence Rates of Clostridium difficile Infection. Clinical Infectious Diseases, 2013, 57, 1304-1307.	5.8	93
64	Virulence and Clinical Outcomes in Clostridium difficile Infection: A Complex Business. Clinical Infectious Diseases, 2013, 56, 906-907.	5.8	12
65	Editorial Commentary: Climbing the Evidentiary Hierarchy for Environmental Infection Control. Clinical Infectious Diseases, 2013, 56, 36-39.	5.8	26
66	Editorial Commentary: Looking to the Future: Vertical vs Horizontal Prevention of Clostridium difficile Infections. Clinical Infectious Diseases, 2013, 57, 1103-1105.	5.8	4
67	Current Status of Clostridium difficile Infection Epidemiology. Clinical Infectious Diseases, 2012, 55, S65-S70.	5.8	366
68	Infection Control in the Multidrug-Resistant Era: Tending the Human Microbiome. Clinical Infectious Diseases, 2012, 54, 707-713.	5.8	82
69	Evaluation of Organizational Culture among Different Levels of Healthcare Staff Participating in the Institute for Healthcare Improvement's 100,000 Lives Campaign. Infection Control and Hospital Epidemiology, 2012, 33, 135-143.	1.8	19
70	Burden of Clostridium difficile Infection in Long-Term Care Facilities in Monroe County, New York. Infection Control and Hospital Epidemiology, 2012, 33, 1107-1112.	1.8	54
71	The Roles of Clostridium difficile and Norovirus Among Gastroenteritis-Associated Deaths in the United States, 1999â€“2007. Clinical Infectious Diseases, 2012, 55, 216-223.	5.8	258
72	Automated Surveillance of Clostridium difficile Infections Using BioSense. Infection Control and Hospital Epidemiology, 2011, 32, 26-33.	1.8	20

#	Article	IF	Citations
73	Using Electronic Health Information to Risk-Stratify Rates of Clostridium difficile Infection in US Hospitals. Infection Control and Hospital Epidemiology, 2011, 32, 649-655.	1.8	41
74	Healthcare Personnel Perceptions of Hand Hygiene Monitoring Technology. Infection Control and Hospital Epidemiology, 2011, 32, 1091-1096.	1.8	52
75	Hospital Capacity during an Influenza Pandemicâ€"Buenos Aires, Argentina, 2009. Infection Control and Hospital Epidemiology, 2011, 32, 87-90.	1.8	5
76	A Case-control Study of Community-associated Clostridium difficile Infection: No Role for Proton Pump Inhibitors. American Journal of Medicine, 2011, 124, 276.e1-276.e7.	1.5	84
77	Clostridium difficileInfection in Outpatients, Maryland and Connecticut, USA, 2002â€"2007. Emerging Infectious Diseases, 2011, 17, 1946-1949.	4.3	26
78	Clostridium difficile Infection Among Children With Cancer. Pediatric Infectious Disease Journal, 2011, 30, 610-612.	2.0	68
79	Risk Factors for and Estimated Incidence of Community-associatedClostridium difficileInfection, North Carolina, USA¹. Emerging Infectious Diseases, 2010, 16, 197-204.	4.3	186
80	Clostridium difficileInfections among Hospitalized Children, United States, 1997â€"2006. Emerging Infectious Diseases, 2010, 16, 604-609.	4.3	213
81	Multicenter Study of Surveillance for Hospital-Onset Clostridium difficile Infection by the Use of ICD-9-CM Diagnosis Codes. Infection Control and Hospital Epidemiology, 2010, 31, 262-268.	1.8	63
82	Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology, 2010, 31, 431-455.	1.8	2,716
83	Cluster of necrotizing enterocolitis in a neonatal intensive care unit: New Mexico, 2007. American Journal of Infection Control, 2010, 38, 144-148.	2.3	21
84	Risk Factors for SARS Transmission from Patients Requiring Intubation: A Multicentre Investigation in Toronto, Canada. PLoS ONE, 2010, 5, e10717.	2.5	252
85	Clostridium difficilein Retail Meat Products, USA, 2007. Emerging Infectious Diseases, 2009, 15, 819-821.	4.3	245
86	Possible Seasonality ofClostridium difficilein Retail Meat, Canada. Emerging Infectious Diseases, 2009, 15, 802-805.	4.3	112
87	Clostridium difficile Strains from Community-Associated Infections. Journal of Clinical Microbiology, 2009, 47, 3004-3007.	3.9	57
88	Undiagnosed cases of fatal Clostridium-associated toxic shock in Californian women of childbearing age. American Journal of Obstetrics and Gynecology, 2009, 201, 459.e1-459.e7.	1.3	39
89	Complete Restriction of Fluoroquinolone Use to Control an Outbreak ofClostridium difficileInfection at a Community Hospital. Infection Control and Hospital Epidemiology, 2009, 30, 264-272.	1.8	81
90	Multicenter Study of the Impact of Community-Onset Clostridium difficile Infection on Surveillance for C. difficile Infection. Infection Control and Hospital Epidemiology, 2009, 30, 518-525.	1.8	25

#	Article	IF	Citations
91	Clostridium difficile Infection in Ohio Hospitals and Nursing Homes During 2006. Infection Control and Hospital Epidemiology, 2009, 30, 526-533.	1.8	99
92	Clostridium difficile Infections in Children. Pediatric Infectious Disease Journal, 2009, 28, 145-146.	2.0	76
93	Clostridium difficileâ€"associated diarrhea: an emerging threat to pregnant women. American Journal of Obstetrics and Gynecology, 2008, 198, 635.e1-635.e6.	1.3	95
94	Vancomycin-Resistant Staphylococcus aureus in the United States, 2002-2006. Clinical Infectious Diseases, 2008, 46, 668-674.	5.8	404
95	The burden of vancomycin-resistant enterococcal infections in US hospitals, 2003 to 2004. Diagnostic Microbiology and Infectious Disease, 2008, 62, 81-85.	1.8	58
96	Assessment of Clostridium difficileâ€"Associated Disease Surveillance Definitions, North Carolina, 2005. Infection Control and Hospital Epidemiology, 2008, 29, 197-202.	1.8	51
97	Outbreak ofEnterococcus gallinarumInfections After Total Knee Arthroplasty. Infection Control and Hospital Epidemiology, 2008, 29, 361-363.	1.8	12
98	Impact of Hydrogen Peroxide Vapor Room Decontamination onClostridium difficileEnvironmental Contamination and Transmission in a Healthcare Setting. Infection Control and Hospital Epidemiology, 2008, 29, 723-729.	1.8	228
99	Comparison of Seven Techniques for Typing International Epidemic Strains of Clostridium difficile : Restriction Endonuclease Analysis, Pulsed-Field Gel Electrophoresis, PCR-Ribotyping, Multilocus Sequence Typing, Multilocus Variable-Number Tandem-Repeat Analysis, Amplified Fragment Length Polymorphism, and Surface Layer Protein A Gene Sequence Typing. Journal of Clinical Microbiology, 2008, 46, 431-437.	3.9	298
100	Short- and Long-Term Attributable Costs of Clostridium difficile-Associated Disease in Nonsurgical Inpatients. Clinical Infectious Diseases, 2008, 46, 497-504.	5.8	168
101	The Changing Spectrum of Clostridium Difficileâ€"Associated Disease. Journal of the American Dental Association, 2008, 139, 42-47.	1.5	6
102	Vancomycin-Resistant Staphylococcus aureus Isolates Associated with Inc18-Like vanA Plasmids in Michigan. Antimicrobial Agents and Chemotherapy, 2008, 52, 452-457.	3.2	120
103	Attributable Outcomes of EndemicClostridium difficileâ€"associated Disease in Nonsurgical Patients. Emerging Infectious Diseases, 2008, 14, 1031-1038.	4.3	148
104	Toxinotype VClostridium difficilein Humans and Food Animals. Emerging Infectious Diseases, 2008, 14, 1039-1045.	4.3	193
105	The Challenges Posed by Reemerging Clostridium difficile Infection. Clinical Infectious Diseases, 2007, 45, 222-227.	5.8	139
106	A Multistate Outbreak of Serratia marcescens Bloodstream Infection Associated with Contaminated Intravenous Magnesium Sulfate from a Compounding Pharmacy. Clinical Infectious Diseases, 2007, 45, 527-533.	5.8	66
107	Confronting Clostridium difficile in Inpatient Health Care Facilities. Clinical Infectious Diseases, 2007, 45, 1274-1276.	5.8	13
108	Multistate Outbreak of Burkholderia cenocepacia Colonization and Infection Associated With the Use of Intrinsically Contaminated Alcohol-Free Mouthwash. Chest, 2007, 132, 1825-1831.	0.8	49

#	Article	IF	Citations
109	Evaluation of Clostridium difficileâ€"Associated Disease Pressure as a Risk Factor for C difficileâ€"Associated Disease. Archives of Internal Medicine, 2007, 167, 1092.	3.8	119
110	Toxic Shock Associated With Clostridium sordellii and Clostridium perfringens After Medical and Spontaneous Abortion. Obstetrics and Gynecology, 2007, 110, 1027-1033.	2.4	100
111	Prevalence of Clostridium difficile environmental contamination and strain variability in multiple health care facilities. American Journal of Infection Control, 2007, 35, 315-318.	2.3	137
112	Bench-to-bedside review: Clostridium difficile colitis. Critical Care, 2007, 12, 203.	5.8	51
113	Moxifloxacin Therapy as a Risk Factor forClostridium difficileâ€"Associated Disease During an Outbreak: Attempts to Control a New Epidemic Strain. Infection Control and Hospital Epidemiology, 2007, 28, 198-201.	1.8	89
114	Recommendations for Surveillance of Clostridium difficileâ€"Associated Disease. Infection Control and Hospital Epidemiology, 2007, 28, 140-145.	1.8	525
115	Clostridium difficile--Associated Disease in a Setting of Endemicity: Identification of Novel Risk Factors. Clinical Infectious Diseases, 2007, 45, 1543-1549.	5.8	241
116	Increasing Blood Culture Use at US Hospital Emergency Department Visits, 2001 to 2004. Annals of Emergency Medicine, 2007, 50, 42-48.e2.	0.6	23
117	Changes in the Epidemiology of Methicillin-Resistant Staphylococcus aureus in Intensive Care Units in US Hospitals, 1992-2003. Clinical Infectious Diseases, 2006, 42, 389-391.	5.8	468
118	Measurement of toxin production by Clostridium difficile â€" Authors' reply. Lancet, The, 2006, 367, 983-984.	13.7	1
119	Improving Antimicrobial Use in the Hospital Setting by Providing Usage Feedback to Prescribing Physicians. Infection Control and Hospital Epidemiology, 2006, 27, 378-382.	1.8	54
120	Cluster of Cases of Severe Acute Respiratory Syndrome Among Toronto Healthcare Workers After Implementation of Infection Control Precautions: A Case Series. Infection Control and Hospital Epidemiology, 2006, 27, 473-478.	1.8	75
121	Clostridium difficileInfection in Patients Discharged from US Short-stay Hospitals, 1996â€"20031. Emerging Infectious Diseases, 2006, 12, 409-415.	4.3	378
122	ICD-9 Codes and Surveillance for Clostridium difficileâ€"associated Disease. Emerging Infectious Diseases, 2006, 12, 1576-1579.	4.3	165
123	Staphylococcus aureusâ€"associated Skin and Soft Tissue Infections in Ambulatory Care. Emerging Infectious Diseases, 2006, 12, 1715-1723.	4.3	269
124	Changing Epidemiology of Clostridium difficile-Associated Disease. Infectious Diseases in Clinical Practice, 2006, 14, 296-302.	0.3	6
125	An Association between Reduced Susceptibility to Daptomycin and Reduced Susceptibility to Vancomycin in Staphylococcus aureus. Clinical Infectious Diseases, 2006, 42, 1652-1653.	5.8	171
126	A Hospital Outbreak of Diarrhea Due to an Emerging Epidemic Strain of Clostridium difficile. Archives of Internal Medicine, 2006, 166, 2518.	3.8	101

#	Article	IF	Citations
127	Trends in Antimicrobial Resistance in Health Careâ€"Associated Pathogens and Effect on Treatment. Clinical Infectious Diseases, 2006, 42, S65-S71.	5.8	121
128	Life-Threatening Sepsis Caused by Burkholderia cepacia From Contaminated Intravenous Flush Solutions Prepared by a Compounding Pharmacy in Another State. Pediatrics, 2006, 118, e212-e215.	2.1	30
129	Clostridium difficile-associated disease: new challenges from an established pathogen.. Cleveland Clinic Journal of Medicine, 2006, 73, 187-197.	1.3	193
130	Clostridium difficileInfection in Patients Discharged from US Short-stay Hospitals, 1996â€"20031. Emerging Infectious Diseases, 2006, 12, 409-415.	4.3	611
131	Severe Community-acquired Pneumonia Due toStaphylococcus aureus, 2003â€"04 Influenza Season. Emerging Infectious Diseases, 2006, 12, 894-899.	4.3	361
132	Vancomycin-resistant staphylococci and enterococci: epidemiology and control. Current Opinion in Infectious Diseases, 2005, 18, 300-305.	3.1	164
133	Late Recognition of SARS in Nosocomial Outbreak, Toronto. Emerging Infectious Diseases, 2005, 11, 322-325.	4.3	14
134	A National Survey of Severe Influenza-Associated Complications among Children and Adults, 2003-2004. Clinical Infectious Diseases, 2005, 40, 1693-1696.	5.8	49
135	Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet, The, 2005, 366, 1079-1084.	13.7	1,321
136	Clostridium difficile: Responding to a New Threat From an Old Enemy. Infection Control and Hospital Epidemiology, 2005, 26, 672-675.	1.8	60
137	Colonization of Human Immunodeficiency Virus-Infected Outpatients in Taiwan with Candida Species. Journal of Clinical Microbiology, 2005, 43, 1600-1603.	3.9	50
138	An Epidemic, Toxin Geneâ€"Variant Strain ofClostridium difficile. New England Journal of Medicine, 2005, 353, 2433-2441.	27.0	1,908
139	Improving Antimicrobial Use: Longitudinal Assessment of an Antimicrobial Team Including a Clinical Pharmacist. Journal of Managed Care Pharmacy, 2004, 10, 152-158.	2.2	18
140	Possible SARS Coronavirus Transmission during Cardiopulmonary Resuscitation. Emerging Infectious Diseases, 2004, 10, 287-293.	4.3	224
141	Wresting SARS from Uncertainty. Emerging Infectious Diseases, 2004, 10, 167-170.	4.3	31
142	Lack of SARS Transmission among Healthcare Workers, United States. Emerging Infectious Diseases, 2004, 10, 217-224.	4.3	69
143	SARS and Pregnancy: A Case Report. Emerging Infectious Diseases, 2004, 10, 345-348.	4.3	128
144	SARS in Healthcare Facilities, Toronto and Taiwan. Emerging Infectious Diseases, 2004, 10, 777-781.	4.3	148

#	Article	IF	Citations
145	Molecular epidemiology of emerging reduced susceptibility to fluoroquinolones in Escherichia coli. Journal of Medical Microbiology, 2004, 53, 85-86.	1.8	3
146	The status of antimicrobial resistance in Taiwan among Gram-positive pathogens: the Taiwan Surveillance of Antimicrobial Resistance (TSAR) programme, 2000. International Journal of Antimicrobial Agents, 2004, 23, 362-370.	2.5	41
147	The status of antimicrobial resistance in Taiwan among gram-negative pathogens: the Taiwan surveillance of antimicrobial resistance (TSAR) program, 2000. Diagnostic Microbiology and Infectious Disease, 2004, 48, 211-219.	1.8	40
148	Vancomycin intermediate and resistant Staphylococcus aureus. What the nephrologist needs to know. Nephrology News & Issues, 2004, 18, 63-4, 66-7, 71-2 passim.	0.1	4
149	Hand Hygiene in the New Millennium: Drawing the Distinction Between Efficacy and Effectiveness. Infection Control and Hospital Epidemiology, 2003, 24, 157-159.	1.8	18
150	Peripartum Transmission of Penicillin-Resistant Streptococcus pneumoniae. Journal of Clinical Microbiology, 2003, 41, 2258-2260.	3.9	26
151	Colonization of HIV-infected outpatients in Taiwan with methicillin-resistant and methicillin-susceptible Staphylococcus aureus. International Journal of STD and AIDS, 2003, 14, 473-477.	1.1	39
152	Hospitalization for Community-Acquired Pneumonia. Chest, 2003, 124, 121-124.	0.8	102
153	Vancomycin-Resistant Enterococci from Humans and Retail Chickens in Taiwan with Unique VanB Phenotype- vanA Genotype Incongruence. Antimicrobial Agents and Chemotherapy, 2002, 46, 525-527.	3.2	60
154	Correlates of Antibiotic Use in Taiwan Hospitals. Infection Control and Hospital Epidemiology, 2001, 22, 565-571.	1.8	12
155	Controlled Comparison of BacT/ALERT FAN Aerobic Medium and BACTEC Fungal Blood Culture Medium for Detection of Fungemia. Journal of Clinical Microbiology, 2001, 39, 622-624.	3.9	47
156	Emergence of Reduced Susceptibility and Resistance to Fluoroquinolones in Escherichia coli in Taiwan and Contributions of Distinct Selective Pressures. Antimicrobial Agents and Chemotherapy, 2001, 45, 3084-3091.	3.2	82
157	Determining the Significance of Coagulase-Negative Staphylococci Isolated From Blood Cultures at a Community Hospital A Role for Species and Strain Identification. Infection Control and Hospital Epidemiology, 2000, 21, 213-217.	1.8	71
158	Proficiency in Detecting Vancomycin Resistance in Enterococci among Clinical Laboratories in Santiago, Chile. Emerging Infectious Diseases, 1999, 5, 839-840.	4.3	2
159	Unrecognised Mycobacterium tuberculosis bacteraemia among hospital inpatients in less developed countries. Lancet, The, 1999, 354, 1159-1163.	13.7	91
160	Controlled Clinical Comparison of bioMeìrieux VITAL and BACTEC NR-660 Blood Culture Systems for Detection of Bacteremia and Fungemia in Adults. Journal of Clinical Microbiology, 1999, 37, 1709-1713.	3.9	7
161	Proficiency of Clinical Laboratories in and near Monterrey, Mexico, To Detect Vancomycin-Resistant Enterococci. Emerging Infectious Diseases, 1999, 5, 143-146.	4.3	9
162	Line-Associated Bloodstream Infections in Pediatric Intensive-Care-Unit Patients Associated with a Needleless Device and Intermittent Intravenous Therapy. Infection Control and Hospital Epidemiology, 1998, 19, 772-777.	1.8	58

#	Article	IF	Citations
163	Linking Antimicrobial Use to Nosocomial Infections: The Role of a Combined Laboratory-Epidemiology Approach. Annals of Internal Medicine, 1998, 129, 245.	3.9	6
164	The global impact of vancomycin-resistant enterococci. Current Opinion in Infectious Diseases, 1997, 10, 304-309.	3.1	10
165	Vancomycin-Resistant Enterococci Outside the Health-Care Setting: Prevalence, Sources, and Public Health Implications. Emerging Infectious Diseases, 1997, 3, 311-317.	4.3	168
166	COMMUNITY-ACQUIRED BACTEREMIA IN ZIMBABWE AND THE GLOBAL COST OF CONTAMINATED BLOOD CULTURES. Pediatric Infectious Disease Journal, 1997, 16, 537-538.	2.0	2